急性心肌梗死患者已用氯吡格雷后再负荷的院内出血与死亡关联
基于ACTION Registry-GWTG 2009–2014数据,比较入院前已用氯吡格雷的STEMI和NSTEMI患者首次24小时内再负荷≥300 mg与维持<300 mg的院内结局。再负荷在STEMI占75.8%、NSTEMI占25.9%;大出血风险无显著差异,STEMI再负荷与院内死亡风险降低相关(OR 0.80),NSTEMI无显著死亡差异。
要点
- 入院前已用氯吡格雷的STEMI患者中75.8%接受再负荷,NSTEMI为25.9%。
- 再负荷与大出血风险无显著差异:STEMI OR 0.98,NSTEMI OR 1.00。
- STEMI再负荷与院内死亡风险降低相关(OR 0.80),NSTEMI无显著差异(OR 1.13)。
核心结论
- 氯吡格雷再负荷在入院前已用氯吡格雷的心梗患者中常见,尤其STEMI;未观察到出血或死亡风险增加,再负荷对多数心梗患者可能安全。
主要发现
- 再负荷患者更年轻、合并症更少,更可能接受直接PCI(STEMI)或早期侵入策略(NSTEMI)。
- 大出血风险再负荷与未再负荷无显著差异:STEMI OR 0.98(95%CI 0.85-1.13),NSTEMI OR 1.00(95%CI 0.90-1.11)。
- STEMI再负荷与院内死亡风险降低相关(OR 0.80,95%CI 0.66-0.96),NSTEMI无显著死亡差异(OR 1.13,95%CI 0.93-1.37)。
临床怎么用
- 对于入院前已用氯吡格雷的STEMI患者,再负荷≥300 mg与较低院内死亡风险相关且未增加大出血,可能考虑再负荷。
- 对于入院前已用氯吡格雷的NSTEMI患者,再负荷未显示死亡获益且不增加出血,决策需个体化。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We sought to determine the association of clopidogrel reloading with in-hospital bleeding and mortality in contemporary practice. METHODS AND RESULTS: We examined clopidogrel reloading for ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients on pre-admission clopidogrel therapy in the ACTION Registry-GWTG from 2009 to 2014. We used inverse probability weighted propensity adjustment to compare in-hospital mortality and major bleeding risks between patients reloaded in the first 24 h with ≥300 mg of clopidogrel vs. those continued on a maintenance (<300 mg) dose. Among the 12 366 patients on pre-admission clopidogrel therapy who were admitted with STEMI, 9369 (75.8%) received a loading dose. Of 39 158 patients with NSTEMI, 10 144 (25.9%) were reloaded. Reloaded patients were younger, had fewer comorbid conditions, and were more likely to be treated with primary PCI (STEMI) or an early invasive strategy (NSTEMI). Risks of major bleeding were not significantly different between patients with and without reloading, whether presenting with STEMI (OR 0.98, 95% CI 0.85-1.13) or NSTEMI (OR 1.00, 95% CI 0.90-1.11). Among STEMI patients, clopidogrel reloading was associated with lower risks of in-hospital mortality (OR 0.80, 95% CI 0.66-0.96), however no significant mortality difference was observed among NSTEMI patients (OR 1.13, 95% CI 0.93-1.37). CONCLUSION: Clopidogrel reloading occurs frequently among MI patients who are on pre-admission clopidogrel therapy, particularly among STEMI patients. We did not observe increased bleeding or mortality risk with clopidogrel reloading, and therefore reloading could be safe for most MI patients.
引用
- Doll JA, Li S, Chiswell K, et al. Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. Eur Heart J. 2018. PMID: 28541452. doi:10.1093/eurheartj/ehx255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。